Compass Therapeutics, Inc.

NASDAQ:CMPX

2.46 (USD) • At close March 14, 2025
Bedrijfsnaam Compass Therapeutics, Inc.
Symbool CMPX
Munteenheid USD
Prijs 2.46
Beurswaarde 340,176,180
Dividendpercentage 0%
52-weken bereik 0.765 - 4.08
Industrie Biotechnology
Sector Healthcare
CEO Dr. Thomas J. Schuetz M.D., Ph.D.
Website https://www.compasstherapeutics.com

An error occurred while fetching data.

Over Compass Therapeutics, Inc.

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical

Vergelijkbare Aandelen

Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc.

MRSN

0.465 USD

InterCure Ltd. logo

InterCure Ltd.

INCR

1.06 USD

Aerovate Therapeutics, Inc. logo

Aerovate Therapeutics, Inc.

AVTE

2.47 USD

Anika Therapeutics, Inc. logo

Anika Therapeutics, Inc.

ANIK

15.91 USD

EyePoint Pharmaceuticals, Inc. logo

EyePoint Pharmaceuticals, Inc.

EYPT

6.52 USD

OraSure Technologies, Inc. logo

OraSure Technologies, Inc.

OSUR

3.51 USD

Utah Medical Products, Inc. logo

Utah Medical Products, Inc.

UTMD

57.3 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)